Additional mutations in the cystic fibrosis (CF) gene were identified in the regions corresponding to the two putative nucleotide (ATP)-binding folds (NBFs) of the predicted polypeptide. The patient cohort included 46 Canadian CF families with well-characterized DNA marker haplotypes spanning the disease locus and several other families from Israel. Eleven mutations were found in the first NBF, 2 were found in the second NBF, but none was found in the R-domain. Seven of the mutations were of the missense type affecting some of the highly conserved amino acid residues in the first NBF; 3 were nonsense mutations; 2 would probably affect mRNA splicing; 2 corresponded to small deletions, including another 3-base-pair deletion different from the major mutation (AF508), which could account for 70% of the CF chromosomes in the population. Nine of these mutations accounted for 12 of the 31 non-AF508 CF chromosomes in the Canadian families. The highly heterogeneous nature of the remaining CF mutations provides important insights into the structure and function of the protein, but it also suggests that DNA-based genetic screening for CF carrier status will not be straightforward.
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The gene responsible for cystic fibrosis (CF) has recently been identified and the major mutation has been defined at the DNA level (1) (2) (3) , providing a direct means for elucidating the basic defect in this disease and for giving an accurate genetic diagnosis. Sequence analysis of overlapping cDNA clones predicts a protein consisting of 1480 amino acids and containing membrane-associated regions and nucleotide (ATP)-binding folds (NBFs) ; this putative protein product has been named the cystic fibrosis transmembrane conductance regulator (CFTR) (2) . The major mutation corresponds to a 3-base-pair (bp) deletion, which results in the loss of a phenylalanine residue at amino acid position 508 (AF508), within the first NBF (NBF1) of CFTR (2, 3) . This mutation accounts for =70% of all CF chromosomes, and haplotype analysis suggests that all AF508 chromosomes are derived from the same origin (3) (4) (5) .
On the basis ofDNA marker haplotype analysis, the remaining 30o of CF chromosomes are expected to be heterogeneous with respect to the nature of the mutations (3). Since each mutation marks a functionally important region of CFTR, it is expected that identification of additional mutations in the CF gene will provide useful information about the structure and function ofthe protein, in understanding the pathophysiology of the disease, and in development of pharmaceutical agents for better treatment of individuals with CF. Furthermore, identification of CF mutations at the DNA level will provide the required information basis for genetic testing, especially when population screening for CF carriers is considered.
Since the major CF mutation occurs within the first NBF of CFTR, it is reasonable to assume that additional mutations might also be found within the two NBFs for the remaining 30% of CF chromosomes. In this communication, we report the result of a survey of the CF gene, in regions corresponding to the two NBFs and the R-domain of the protein, for the presence of additional mutations.
MATERIALS AND METHODS DNA Samples. The majority of CF families used in this study have been described (6) . Extensive DNA marker haplotype information was available for the CF chromosomes in 46 Canadian families (3) . A small number of additional CF families with unique geographic or ethnic backgrounds were included in the mutational screening; the ones reported here were recruited in the Chaim Sheba Medical Center in Israel.
Polymerase Chain Reactions (PCRs). DNA sequences spanning individual exons were amplified by PCR with oligonucleotide primers located in the respective flanking introns. The general procedure for PCR has been described (7, 8) . The specific oligonucleotide primers used for the amplification of individual exon sequences are listed in 
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Allele-Specific Oligonucleotide (ASO) Hybridization. The oligonucleotide hybridization condition has been described (3). The normal and mutant specific oligonucleotides are listed in Table 2 Table 3 . A total of 13 mutations were identified: 11 ofthem were located in the first NBF and 2 were in the second NBF, but none were in the R-domain. Two of these mutations, G551D (12) and W1282X (14) , have been reported previously; 2 (Table 3 ) appeared to be rare in the population, as only single cases were detected, two of the mutations, A455E and G551D, occurred more than once among the present Canadian chromosome population-two were detected for A455E and three were detected for G551D. In an earlier study, Cutting et al. (12) reported that 6 of 35 (17%) non-AF508 CF chromosomes screened carried the G551D mutation. Preliminary data from studies ofother populations indicated that the G542X and S5491 mutations were also relatively abundant; for example, 5 of 59 (8.4%) non-AF508 CF chromosomes were found to carry G542X in the Jewish population in Israel and 1 of the CF Arabic patients was homozygous S5491. Together, these four mutations may account for 10-20o of the non-AF508 CF chromosomes.
In addition to the mutations described above, we have detected three DNA sequence variations that occur on normal chromosomes: two of them, at nucleotide positions 1716 (G or A) and 2694 (T or G), do not appear to affect the 
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encoded amino acids, but the third one, at position 1540 (A or G), results in either methionine or valine.
DNA Marker Haplotype. Determination of the DNA marker haplotype associated with each of the mutations is important, not only in providing a reference for mutant classification but also in tracing the origins of mutations, thereby gaining insights into the possible cause for the high frequency of CF mutations in the Caucasian population.
Our previous study showed that chromosomes carrying the AF508 mutation were derived from the same origin (3) . To determine whether ancestral relationships existed among CF chromosomes carrying the other mutations, DNA marker haplotypes were analyzed. As shown in Fig. 1 , the chromosomes containing A455E and G551D share the same haplotypes for DNA markers spanning the CF gene, groups lb and III, respectively. The G551D chromosomes detected by Cutting et al. (12) also appear to have haplotype III. The A1507 mutation described here carries a group III haplotype ( Fig. 1) and it is in good agreement with the partial haplotype data for another example of this mutation independently identified (M. Schwarz, C. Summers, L. Heptinstall, C. Newton, A. Markham, R. Cain, and M. Super, unpublished data). Therefore, these haplotype data suggest that CF chromosomes harboring the same mutation were probably derived from a common origin.
Chromosomes within the same haplotype group, however, may harbor different mutations (e.g., those in groups Ila and Medical Sciences: Kerem et al.
III; Fig. 1 ). It is of interest to note that four different mutations have already been identified on CF chromosomes with haplotype III, which is infrequent among the N chromosomes (3). The number of mutations in the CF gene would therefore greatly exceed that predicted on the basis of haplotype analysis (3), as has been observed thus far. The extended DNA marker haplotypes were not determined for five of the CF mutations-namely, G542X, W1282X, S549R, S549I, and 1717-1G -* A-because the patients in whom these mutations were found were all recently recruited from Israel. The G542X mutation was first found in an Ashkenazic Jewish patient whose other CF chromosome was W1282X; S549R was discovered in a Moroccan-Jewish individual who also carried AF508; S549I and 1717-1G -* A were both first detected in Arabic patients.
On the basis of ASO-hybridization and haplotype data, we previously suspected that one of the CF chromosomes with haplotype group III might carry a recurring AF508 mutation (3) . Direct DNA sequence analysis, however, revealed that the mutation carried by this chromosome was AI507 (Table 3 and Fig. 1 ), differing from AF508 by a single nucleotide, A instead of T. The marked difference between haplotype III and haplotype Ia, which is associated with AF508, suggests that the two mutations are derived from different origins.
Hot Spots for Mutations. There appeared to be a difference in distribution of mutations between the two NBFs-the number of mutations detected in the first NBF (exons 9-12) and 6 times that in the second NBF (exons [19] [20] [21] [22] [23] . In addition, although the sample size is small, exon 11 seems to contain the most mutations (this study; ref. 12). It is possible that the first NBF, particularly the exon 11 region, is more critical for CFTR function. Alternatively, the DNA sequences encoding the first NBF may be relatively more unstable than other regions. The latter explanation is supported by two lines of observations. First, only two 3-bp deletions have so far been detected in the CF gene; both occur in the same region within exon 10. Second, several sequence alterations have been detected for the AGT codon for serine at position 549 in exon 11; while Cutting et al. (12) reported a change of this codon to AAT for asparagine (S549N), this study shows two additional mutations at this position-T to G transversion for S549R and G to T transversion for S549I.
Implications in Protein Structure. Since no major deletion or rearrangement has been detected in CF, the discovery of nonsense, frameshift, and splicing mutations in the gene is surprising. It is also somewhat surprising that no mutation was found in the R-domain, a region that was thought to have a regulatory function (2). The only mutation reported for the region so far was a 2-bp insertion toward the end of this domain (19) . The paucity of mutations in this region suggests that either the R-domain is not critical for function or mutations in this part of the protein cannot be tolerated. On the other hand, patients homozygous for nonsense (ref. 20 ; H. Cuppens, P. Marynen, C. De Boeck, F. Baets, E. Eggermont, H. Van den Berghe, and J. J. Cassiman, unpublished data) or splicing (data not shown) mutations have been detected, suggesting that total loss of CFTR function is not incompatible with life.
The occurrence of AI507 and AF508 in the same region ofthe presumptive ATP-binding domain of CFTR is noteworthy. First, it is unclear which 3 bp were deleted in both cases (Fig.  2) . In A1507, the deleted amino acid may be the isoleucine residue at position 506. Second, the amino acid residues involved, Phe-508 and Ile-507 (or Ile-506), are located in a polypeptide segment linking the two highly conserved regions believed to be the nucleotide contacting points (2, 22) . Deletion of either one of the two amino acids is sufficient to disrupt the gene function. Furthermore, amino acid substitutions in this region have been found in two rare variants of normal chromosomes (with Phe-508 replaced by a cysteine and Ile-506 replaced by a valine) without apparent loss of function of the protein (23) . Therefore, the length of the polypeptide may be more important than the actual amino acid residues in this region for CFTR. Since the length ofthe linking segment varies among different ATP-binding proteins and the amino acid sequences are less conserved, the functional importance of Ile-507 and Phe-508 is probably unique to CFTR.
Five of the missense mutations (A455E, S5491, S549R, G551D, R560T) occurred at amino acid residues highly conserved among the various NBFs from different proteins, suggesting that these residues are critical in ATP binding (2) . The role of the two other missense mutations (Y563N, P574H) within the NBFs is not immediately apparent, although both mutations would drastically change the amino acid types. It is anticipated, however, that knowledge about these and other (12, 14, 19, 24) naturally occurring mutations will be an essential part in understanding the structure and function of the protein. In conjunction with development of three-dimensional structural analysis and tests for the biological activities of CFTR, it should be possible to define the role of each of these residues at the molecular level and, eventually, the function of the protein.
Clinical Phenotype. Our previous studies (3, 25) showed that the pancreatic function of CF patients was at least in part predisposed by their genotypes at the CF locus. We hypothesized that CF mutations could be divided into two classesnamely, severe and mild (with respect to pancreatic involvement). Patients with two severe alleles are expected to be pancreatic insufficient (PI) and patients with one or two copies of mild alleles are pancreatic sufficient (PS). The AF508 mutation has been classified as a severe allele and, as expected, patients homozygous for AF508 are almost certainly PI (3, 13) .
To examine the clinical consequence of the mutations described in this report, the clinical status of each individual carrying these mutations was reviewed. (11) . This method may also be applied to AI507; as shown in Fig. 2 (4, 5, 12) .
It is perhaps also important to point out the pitfalls of some of the common means of DNA diagnosis. For example, both S549N (12) (15) and several mutations described here (Q493X, S549R, and 3659delC); this method usually works well but it requires very careful temperature control to distinguish different sequences. These examples illustrate that extreme caution should be used with any DNA testing procedure; testing ofa large number of normal chromosomes, particularly those of the same haplotypes, and quality control should be mandatory before any broad-scale screening is implemented. Furthermore, it has been suggested that broadscale population screening for CF carriers should not begin until at least 95% of the mutations have been identified (21) .
